Example: Heart Attack

Search clinical trials for: Alkylating Agents

Total 5571 results

NCT01091168

Completed

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

Conditions: Breast Cancer; Metastases
NCT01189643

Active, not recruiting

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Conditions: Sarcoma; Desmoplastic Small Round Cell Tumor (DSRCT)
NCT02856048

Active, not recruiting

Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer

Conditions: Cancer; Toxicity Due to Chemotherapy; Sarcoma; Osteosarcoma; Lymphoma; Ewing Sarcoma
NCT03217097

Recruiting

MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents

Conditions: Neuroendocrine Tumors
NCT00001498

Completed

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

Conditions: Breast Cancer; Breast Neoplasms
NCT00001493

Completed

Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer

Conditions: Breast Neoplasms; Neoplasm Metastasis
NCT00003635

Completed

506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents

Conditions: Leukemia
NCT01397149

Terminated

Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)

Conditions: Chronic Lymphocytic Leukemia; Thrombocytopenia
NCT01864109

Recruiting

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Conditions: Newly Diagnosed Ewing Sarcoma
NCT01659606

Recruiting

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

Conditions: Dyskeratosis Congenita; Hoyeraal Hreidarsson Syndrome; Revesz Syndrome; Aplastic Anemia
NCT02678975

Active, not recruiting

Disulfiram in Recurrent Glioblastoma

Conditions: Glioma; Glioblastoma
NCT00448266

Terminated

Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

Conditions: Breast Cancer
NCT00623077

Terminated

MT2004-30: Tomotherapy for Solid Tumors

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Liver Cancer; Retinoblastoma; Sarcoma
NCT00002680

Completed

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer

Conditions: Breast Cancer
NCT02158234

Active, not recruiting

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

Conditions: Squamous Cell Carcinoma of the Head and Neck
NCT00281983

Completed

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Conditions: Chronic Lymphocytic Leukemia
NCT00899795

Completed

Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers

Conditions: Leukemia; Myelodysplastic Syndromes
NCT04278040

Recruiting

Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis

Conditions: Non-cystic Fibrosis Bronchiectasis
NCT03886233

Not yet recruiting

Treatment Outcome of Uveitis in Autoimmune Diseases

Conditions: Autoimmune Uveitis
NCT03557359

Recruiting

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Conditions: Gliomas
NCT00049686

Completed

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
NCT01282424

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

Conditions: Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma
NCT00025129

Completed

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

Conditions: Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
NCT00049699

Completed

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

Conditions: Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
NCT00655395

Terminated

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)